Recent advances in systemic therapy for hepatocellular carcinoma

被引：154
作者：
Zhang, Huajun [1 ]
Zhang, Wuyang [2 ]
Jiang, Longying [1 ,3 ]
Chen, Yongheng [1 ,4 ]
机构：
[1] Cent South Univ, Xiangya Hosp, Dept Oncol, NHC,Key Lab Canc Prote,Lab Struct Biol, Changsha 410008, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Clin Skills Training Ctr, Changsha 410008, Hunan, Peoples R China
[3] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Hunan, Peoples R China
[4] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha 410008, Hunan, Peoples R China
来源：
BIOMARKER RESEARCH | 2022年 / 10卷 / 01期
基金：
中国国家自然科学基金;
关键词：
Hepatocellular carcinoma; Molecular targeted therapy; Immunotherapies; Combination; ENDOTHELIAL GROWTH-FACTOR; TUMOR-ASSOCIATED MACROPHAGES; RECEPTOR TYROSINE KINASES; NIVOLUMAB PLUS IPILIMUMAB; PHASE-III; DOUBLE-BLIND; OPEN-LABEL; T-CELLS; 1ST-LINE TREATMENT; ANTITUMOR-ACTIVITY;
D O I：
10.1186/s40364-021-00350-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially with conventional cytotoxic drugs, is usually ineffective. For more than a decade, sorafenib has been the only systemic drug that has been proven to be clinically effective for treating advanced HCC. However, over the past three years, the rapid progress of molecular targeted therapies has dramatically changed the treatment landscape for advanced HCC. Immune checkpoint therapies are now being incorporated into HCC therapies, and their combination with molecular targeted therapy is emerging as a tool to enhance the immune response. In this review, we summarize the development and progress of molecular targeted agents and immunotherapies in HCC.
引用
收藏
页数：21
相关论文
共 154 条
[81]   Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine [J].
Kwilas, Anna R. ;
Ardiani, Andressa ;
Donahue, Renee N. ;
Aftab, Dana T. ;
Hodge, James W. .
JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12
[82]   Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib [J].
Lee, Dae-Won ;
Cho, Eun Ju ;
Lee, Jeong-Hoon ;
Yu, Su Jong ;
Kim, Yoon Jun ;
Yoon, Jung-Hwan ;
Kim, Tae-Yong ;
Han, Sae-Won ;
Oh, Youn ;
Im, Seock-Ah ;
Kim, Tae-You ;
Lee, Youngeun ;
Kim, Haeryoung ;
Lee, Kyung-Hun .
CLINICAL CANCER RESEARCH, 2021, 27 (03) :713-718
[83]  
Lee MS, 2020, LANCET ONCOL, V21, P808, DOI 10.1016/S1470-2045(20)30156-X
[84]   Structures of β-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling [J].
Lee, Sangwon ;
Choi, Jungyuen ;
Mohanty, Jyotidarsini ;
Sousa, Leiliane P. ;
Tome, Francisco ;
Pardon, Els ;
Steyaert, Jan ;
Lemmon, Mark A. ;
Lax, Irit ;
Schlessinger, Joseph .
NATURE, 2018, 553 (7689) :501-+
[85]   Tim-3 expression and its role in hepatocellular carcinoma [J].
Liu, Feifei ;
Liu, Yanning ;
Chen, Zhi .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
[86]   Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply [J].
Liu, Ken ;
Zhang, Xiang ;
Xu, Weiqi ;
Chen, Jinbiao ;
Yu, Jun ;
Gamble, Jennifer R. ;
McCaughan, Geoffrey W. .
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2017, 8
[87]   Sorafenib in advanced hepatocellular carcinoma [J].
Llovet, Josep M. ;
Ricci, Sergio ;
Mazzaferro, Vincenzo ;
Hilgard, Philip ;
Gane, Edward ;
Blanc, Jean-Frederic ;
Cosme de Oliveira, Andre ;
Santoro, Armando ;
Raoul, Jean-Luc ;
Forner, Alejandro ;
Schwartz, Myron ;
Porta, Camillo ;
Zeuzem, Stefan ;
Bolondi, Luigi ;
Greten, Tim F. ;
Galle, Peter R. ;
Seitz, Jean-Francois ;
Borbath, Ivan ;
Haussinger, Dieter ;
Giannaris, Tom ;
Shan, Minghua ;
Moscovici, Marius ;
Voliotis, Dimitris ;
Bruix, Jordi .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) :378-390
[88]  
Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]
[89]   Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities [J].
Lu, Chen ;
Rong, Dawei ;
Zhang, Betty ;
Zheng, Wubin ;
Wang, Xuehao ;
Chen, Ziyi ;
Tang, Weiwei .
MOLECULAR CANCER, 2019, 18 (01)
[90]   Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects [J].
Lu, Xiaoyun ;
Chen, Hao ;
Patterson, Adam V. ;
Smaill, Jeff B. ;
Ding, Ke .
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (06) :2905-2915
45678910111213